Theravance Biopharma
TBPH
84 hedge funds and large institutions have $1.62B invested in Theravance Biopharma in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 12 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
1.16% more ownership
Funds ownership: 86.78% → 87.94% (+1.2%)
11% less funds holding
Funds holding: 94 → 84 (-10)
12% less capital invested
Capital invested by funds: $1.84B → $1.62B (-$224M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
82% less call options, than puts
Call options by funds: $394K | Put options by funds: $2.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.1M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$5.95M |
| 3 |
BlackRock
New York
|
+$5.44M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.13M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$8.85M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$4.89M |
| 3 |
First Manhattan
New York
|
-$4.62M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.87M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.25M |
TBPH Hedge Fund Activity: Q3 2017 in Review
84 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2017, worth a combined $1.62B — down 12% from $1.84B a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TBPH and 3 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 36 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $32.1M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $8.85M sold.
- 84 institutional investors held Theravance Biopharma (TBPH) as of Q3 2017, down from 94 in Q2 2017.
- Funds reported $1.62B of Theravance Biopharma stock for Q3 2017, down 12% quarter-over-quarter.
- 3 funds opened new Theravance Biopharma positions in Q3 2017 and 12 closed out, a net change of -9 holders.
- The largest Theravance Biopharma buyer in Q3 2017 was T. Rowe Price Associates, an estimated $32.1M added.
- The largest Theravance Biopharma seller in Q3 2017 was Marshall Wace North America, an estimated $8.85M sold.
Based on aggregated 13F filings for Q3 2017.